Intrexon Corp (XON) Releases Earnings Results, Misses Expectations By $-0.14 EPS

Intrexon Corp (XON) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $-0.42 earnings per share for the quarter, missing the analyst consensus estimate by $-0.14. Analysts had a consensus of $-0.28. The company posted revenue of $52.50 million in the period, compared to analysts expectations of $53.78 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.

Intrexon Corp closed down -1.66 points or -5.78% at $27.05 with 22,95,801 shares getting traded on Monday. Post opening the session at $30.1, the shares hit an intraday low of $26.918 and an intraday high of $30.15 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Dec 14, 2015, Randal J Kirk (CEO) purchased 124,475 shares at $29.84 per share price. According to the SEC, on Dec 4, 2015, Krish S Krishnan (Chief Operating Officer) sold 20,900 shares at $33.02 per share price. On Dec 4, 2015, Suma Krishnan (SVP–Product Development) sold 20,900 shares at $33.02 per share price, according to the Form-4 filing with the securities and exchange commission.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Intrexon Corp

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.